PE20221314A1 - DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION - Google Patents

DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION

Info

Publication number
PE20221314A1
PE20221314A1 PE2022000441A PE2022000441A PE20221314A1 PE 20221314 A1 PE20221314 A1 PE 20221314A1 PE 2022000441 A PE2022000441 A PE 2022000441A PE 2022000441 A PE2022000441 A PE 2022000441A PE 20221314 A1 PE20221314 A1 PE 20221314A1
Authority
PE
Peru
Prior art keywords
methods
dosage forms
enantiomerically enriched
bupropion
pure bupropion
Prior art date
Application number
PE2022000441A
Other languages
Spanish (es)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2019/052210 external-priority patent/WO2020061486A2/en
Priority claimed from US16/830,637 external-priority patent/US20200222339A1/en
Priority claimed from US16/907,691 external-priority patent/US11433035B2/en
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of PE20221314A1 publication Critical patent/PE20221314A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Abstract

Se refiere a una forma de dosificacion para el tratamiento de una afeccion en un ser humano, la cual comprende el (S)-bupropion que es por lo menos el 95 por ciento enantiomericamente puro o un exceso enantiomerico de (S)-bupropion, en donde la forma de dosificacion se administra por la via oral una vez o dos veces al dia al ser humano.Refers to a dosage form for the treatment of a condition in a human, which comprises (S)-bupropion that is at least 95 percent enantiomerically pure or an enantiomeric excess of (S)-bupropion, in wherein the dosage form is administered orally once or twice daily to the human.

PE2022000441A 2019-09-20 2020-08-18 DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION PE20221314A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
PCT/US2019/052210 WO2020061486A2 (en) 2018-09-20 2019-09-20 Dosage forms and methods for enantiomerically enriched or pure bupropion
US202062971174P 2020-02-06 2020-02-06
US202062978626P 2020-02-19 2020-02-19
US202062992060P 2020-03-19 2020-03-19
US16/830,637 US20200222339A1 (en) 2018-09-20 2020-03-26 Dosage forms and methods for enantiomerically enriched or pure bupropion
US16/907,691 US11433035B2 (en) 2018-09-20 2020-06-22 Dosage forms and methods for enantiomerically enriched or pure bupropion
PCT/US2020/046755 WO2021055124A1 (en) 2019-09-20 2020-08-18 Dosage forms and methods for enantiomerically enriched or pure bupropion

Publications (1)

Publication Number Publication Date
PE20221314A1 true PE20221314A1 (en) 2022-09-07

Family

ID=74884634

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000441A PE20221314A1 (en) 2019-09-20 2020-08-18 DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION

Country Status (14)

Country Link
EP (1) EP4031121A4 (en)
JP (2) JP2022549192A (en)
KR (1) KR20220066930A (en)
CN (1) CN114423417A (en)
AU (2) AU2020349419B2 (en)
BR (1) BR112022005045A2 (en)
CA (1) CA3154718A1 (en)
CO (1) CO2022003126A2 (en)
CR (1) CR20220119A (en)
EC (1) ECSP22030119A (en)
IL (1) IL291514A (en)
MX (1) MX2022003346A (en)
PE (1) PE20221314A1 (en)
WO (1) WO2021055124A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002501890A (en) * 1998-01-29 2002-01-22 セプラコア インコーポレーテッド Pharmaceutical use of optically pure (+)-viewpropion
US6150420A (en) * 1998-06-01 2000-11-21 Theramax, Inc. Method for enhanced brain delivery of bupropion
US20190216800A1 (en) * 2013-11-05 2019-07-18 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
MX2013014166A (en) * 2013-12-03 2015-06-10 Inst De Investigacion En Quimica Aplic S A De C V Active enantiomers and the salts thereof for treating obesity.
US9732031B2 (en) * 2013-12-20 2017-08-15 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
KR20210003091A (en) * 2018-02-23 2021-01-11 액섬 테라퓨틱스, 인크. Dosage forms and methods for enantiomerically enriched or pure bupropion

Also Published As

Publication number Publication date
JP2024059812A (en) 2024-05-01
CA3154718A1 (en) 2021-03-25
EP4031121A1 (en) 2022-07-27
BR112022005045A2 (en) 2022-07-05
KR20220066930A (en) 2022-05-24
AU2020349419B2 (en) 2023-11-02
AU2024200081A1 (en) 2024-01-25
ECSP22030119A (en) 2022-05-31
IL291514A (en) 2022-05-01
AU2020349419A1 (en) 2022-03-24
CO2022003126A2 (en) 2022-04-19
CR20220119A (en) 2022-06-22
MX2022003346A (en) 2022-04-11
EP4031121A4 (en) 2022-11-30
CN114423417A (en) 2022-04-29
WO2021055124A1 (en) 2021-03-25
JP2022549192A (en) 2022-11-24

Similar Documents

Publication Publication Date Title
CL2021001810A1 (en) Combination of dextromethorphan and bupropion for the treatment of depression
CL2020002512A1 (en) Treatment of hidradenitis suppurativa using jak inhibitors.
AR048833A1 (en) PROCEDURE FOR THE TREATMENT OF PREMENSTRUAL DISORDERS AND OTHER FEMALE SEXUAL DISORDERS
WO2020061486A3 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
UY35624A (en) USE OF HIGH DOSE PRIDOPIDINE TO TREAT HUNTINGTON'S DISEASE
CL2019003924A1 (en) Use of pridopidine for the treatment of functional decline. (divisional application 201900485).
MX2018003778A (en) Oral care mouthpiece.
CL2019002218A1 (en) Triple combination formulations and methods to treat or reduce the risk of cardiovascular disease.
AR111374A1 (en) USE OF LIK066 IN PATIENTS WITH HEART FAILURE
MX2021002322A (en) Novel methods.
MX2022015629A (en) Use of vibegron to treat overactive bladder.
NI202000056A (en) DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION
CO2022008001A2 (en) Methods for treating depressive disorders
UY38308A (en) ORAL ADMINISTRATIVE PHARMACEUTICAL DOSAGE FORM WITH MODIFIED RELEASE
NO20082672L (en) Use of cycletanine and other fluoropyridines for the treatment of systolic-dominant hypertension, isolated hypertension, increased pulse pressure and general hypertension
PE20221314A1 (en) DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION
CO6470875A2 (en) A COMPOSITE TO USE IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES
CL2023000764A1 (en) Multiparticulate dosage forms comprising deutetrabenazine
CL2004000984A1 (en) ORAL DOSAGE FORM OF A MAGNESIUM SALT OF (S) -PANTOPAZOL, FOR THE PROPHYLAXIS OR TREATMENT OF A CONDITION ASSOCIATED TO INHIBIT THE PROTONIC PUMP.
AR109760A1 (en) COMPOSITIONS AND METHODS TO TREAT ALZHEIMER'S EVIL AND PARKINSON'S DISEASE
PL425832A1 (en) Genistein and its composition to be used in treatment of Alzheimer disease
EA202191907A1 (en) APPLICATION OF VIBEGRON FOR TREATMENT OF HYPERACTIVE BLADDER
UA117043U (en) METHOD OF TREATMENT OF CHRONIC PERIODONTITIS
PE20210370A1 (en) METHODS TO MODULATE PLASMA LEVELS OF TETRABENAZINE METABOLITES USING BUPROPION
Boudewijns Indoor-photosensitivity and alopecia: 3 case reports